Загрузка...
Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement
PURPOSE: Prospective, double-blind studies in orthopaedic patients have been conducted using the direct thrombin inhibitor dabigatran etexilate (hereafter referred to as dabigatran), with two doses investigated and approved for adults (220 mg and 150 mg once daily) to prevent venous thromboembolism...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer-Verlag
2011
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3311818/ https://ncbi.nlm.nih.gov/pubmed/22095136 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00264-011-1393-5 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|